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Detection of urinary interleukin-8 in glomerular diseases
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Detection of urinary interleukin-8 in glomerular diseases. To clarify the
mechanism of neutrophil infiltration in glomerulonephritis, both urinary
and plasma levels of a potent neutrophil chemotactic cytokine, interleu-
kin-8 (IL-8), were measured in 40 healthy volunteers and 96 patients with
various renal diseases. The plasma IL-8 levels were less than 16 pg/mI. The
urinary IL-8 levels were elevated in several renal diseases including IgA
nephropathy (17 of 43), acute glomerulonephritis (4 of 6), lupus nephritis
(11 of 15), purpura nephritis (2 of 4), membranoproliferative glomerulo-
nephritis (1 of 1), and cryoglobulinemia (2 of 2). IL-8 was detected
immunohistochemically in diseased glomeruli, suggesting its local produc-
tion. Elevated urinary IL-8 levels during the acute phase or exacerbations
were found to be decreased during spontaneous or steroid pulse therapy-
induced convalescence in all patients examined. The urinary IL-8 levels
were higher in patients with glomerular leukocyte infiltration than in those
without infiltration. Collectively, local production of IL-8 in diseased
glomeruli might be involved in the pathogenesis of the glomerular diseases
and measurement of IL-8 in the urine might be useful for monitoring the
glomerular diseases.
Glomerular hypercellularity in the acute phase of glomerular
diseases is caused predominantly by intraglomerular polymorpho-
nuclear leukocyte and mononuclear cell infiltrations. However,
the precise mechanism causing the infiltration of polymorphonu-
clear leukocytes remains to be investigated. Accumulating evi-
dence indicates that inflammatory cytokines, such as interleukin-1
(IL-i) [1], tumor necrosis factor-a (TNF-a) [1] and interleukin-6
(IL-6) [2], may play an important role in the pathogenesis of
glomerular diseases and are involved in the acute exacerbations
[3]. Recent studies indicated that the urinary excretion of IL-6
reflected its local production, either by cells resident in the
glomeruli or by infiltrating cells [4, 5]. The results suggested that
the measurement of the urinary excretion of IL-6 was useful for
evaluating the renal damage and monitoring the disease activities.
We observed that a novel neutrophil chemotactic cytokine,
interleukin-8 (IL-8) [6], played a causative role in neutrophil
infiltration in acute inflammation [7]. IL-8, originally described as
a secreted product from LPS-stimulated human peripheral blood
monocytes [8], is also secreted by various types of non-leukocytic
cells, including dermal fibroblasts [9] and endothelial cells [10].
Furthermore, recent studies indicated that IL-8 was produced by
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mesangial cells [11] or renal epithelial cells [12] in response to
lipopolysaccharide, IL-i, or TNF-a.
To examine the possibility that locally-produced IL-8 partici-
pates in the pathophysiology of the acute phase of glomerular
disease by recruiting leukocytes, particularly, neutrophils, we
determined here both urinary and plasma levels of IL-8 in patients
with various renal diseases. We also investigated the relationship
between IL-8 levels and disease activity.
Methods
Patients
Forty healthy volunteers and 96 patients with primary or
secondary glomerular diseases were evaluated in this study. The
patients in this study were chosen randomly. There were 70 males
and 66 females with a median age of 39.7 years (range 4 to 82
years). The clinical profiles of normal volunteers and patients are
summarized in Table 1. Among these patients, 88 patients had the
diagnosis verified by renal biopsy, while 6 acute glomerulonephri-
tis (AGN) patients and 2 lupus nephritis patients were clinically
diagnosed without pathological analyses. Patients of AGN showed
the symptoms of acute nephritic syndrome, such as hematuria and
edema, after the streptococcal infections. Renal biopsies were not
carried out since their symptoms resolved without special medi-
cation within a few weeks. Urinary tract infections and pyuria
were negated in all cases by means of bacterial cultures and/or the
microscopic findings since urinary tract infection itself is associ-
ated with increased urinary IL-8 levels [13]. Whenever possible,
patients did not receive any immunosuppressive agents before
collecting samples. However, 17 patients (1 cryoglobulinemia, 13
lupus nephritis patients, and 3 IgA nephropathy patients) were in
a clinically active state and were treated with methylprednisolone
pulse therapy (500 mg/day, 3 days) during this study. This study
was approved by the Drug Ethics Committee of Kanazawa
University Hospital. All renal biopsies were performed with the
consent of the patients.
Pathological studies
Eighty-eight kidney specimens were obtained by renal biopsy.
Two observers, without knowledge of the clinical course, exam-
ined the renal tissue under light microscopy to establish the
diagnosis by standard pathological methods. For the lupus nephri-
tis patients, World Health Organization (WHO) criteria were
used for the light microscopic classification of the major forms
and the active lesions of lupus nephritis [14]. The "activity index
(Al)" of the histological appearance was also calculated according
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Table 1. Patients' profiles with respect to diagnosis, the presence of glomerular leukocyte infiltration, glomerular expression of IL-8 and urinary
IL-8 levels
Diagnosis
No. of
patients
(male:female)
Age
years
(mean)
Glomerular
leukocyte
infiltration
Glomerular
expression
of IL-8
Urinary IL-8 levels
pg/mg creatinine
Healthy volunteers 40 (20:20) 4—75 (40.0) ND ND 0
IgA nephropathy 43 (22:21) 16—70 (39.0) 9/26 (35%) 3/25 (12%) 80.6 42.0
with acute exacerbation or onset 15 (3:12) 16—70 (32.3) 4/4(100%) 2/3(67%) 203.4 116.5
without acute exacerbation or onset 28 (19:9) 16—60 (42.5) 5/22 (23%) 1/22 (5%) 14.8 12.3
AGN 6 (3:3) 4—8 (5.0) ND ND 63.4 37.8
MPGN 1(1:0) 62 1/1 1/1 175.0
MCNS 3 (2:1) 32—63 (52.6) 0/3 (0%) 0/3 (0%) 0
FGS 10(6:4) 17—63 (37.8) 0/10(0%) 0/10 (0%) 0
MN 12(10:2) 45—67 (58.6) 0/12(0%) 0/12 ((0%) 0
Lupus nephritis 15 (3:12) 16—53 (33.4) 5/12(41%) 1/7(14%) 98.1 38.7
Purpura nephritis 4(2:2) 4—72 (38.7) 1/4 (25%) 0/0 47.7 27.8
Cryoglobulinemia 2 (1:1) 59—82 (70.5) 1/1 1/1 108.6 105.7
Total 136 (70:66) 4—82 (39.7) 17/69 6/59
Abbreviations are: AGN, acute glomerulonephritis; MPGN, membranoproliferative glomerulonephritis; MCNS,
syndrome; FGS, focal glomeruloscierosis; MN, membranous nephropathy; ND, not done. Values are mean SEM.
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Fig. 1. Urinary IL-8 levels in patients with
various renal diseases. Open circles indicate the
patients with acute exacerbation or onset while
closed ones indicate those without acute
exacerbation or onset. For lupus nephritis
patients, (LI) indicates patients with more than
6.0 of activity index.
to the methods of National Institute of Health (NIH) described by
Austin et al [15].
Immunohisrochemical studies
The presence of IL-8 protein was demonstrated immunohisto-
chemically on fresh tissue specimens by using the indirect avidin-
biotinylated peroxidase complex method with a specific murine
monoclonal anti-human IL-8 (clone WS-4) antibody [16]. A
polyclonal mouse IgG antibody that had been absorbed with both
human liver powder and immunoglobulin was used as the negative
control. Two immunohistochemistry observers were totally blind
to urinary IL-8 levels and the clinical course.
Urinaty and plasma IL-8 measurements
Spontaneously-voided midstream urines and plasma were col-
lected at the same time. All of the 96 cases were not receiving any
treatment, and from 69 cases, urine and plasma were collected on
the morning of renal biopsy. Ten ml of the each urine was spun at
200 X g for five minutes, and the supernatant was used for this
ELISA. The specimens were kept at —70°C until the measure-
ment of IL-8. Both urinary and plasma IL-8 levels were deter-
mined by ELISA, using a monoclonal antibody (clone WS-4) as a
capture and a rabbit antibody as a second antibody essentially as
previously described [16], except that the dilution buffer was
changed to 1% BSA (Sigma Chemical Co., St. Louis, Missouri,
USA) in PBS containing 0.05% Tween 20. This system is highly
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Fig. 2. Comparison of urinaiy IL.8 levels in several diseases at acute onset
or exacerbation with those at convalescence. Symbols are: (•) IgA nephrop-
athy; (0) MPGN; (0) purpura nephritis.
specific for IL-8, since there was no cross reactivity with other
chemokines including platelet basic protein, platelet factor 4,
growth related gene and monocyte chemotactic and activating
factor. The recovery rate was confirmed to be more than 95% up
to 10 ng/ml in this ELISA system. IL-8 was very stable [161 and the
in vitro generation of IL-8 in urine samples containing cells could
be excluded in this system, since the supernatants were obtained
immediately after the collection of urine. All assays were per-
formed at least in duplicate. The detection limit of this ELISA
system for IL-8 was less than 16 pglml. Urinary IL-8 level was
standardized by the amount of creatinine in the urine.
Statistics
Statistical significance was analyzed using Student's t-test for
paired or unpaired data while correlation coefficiency was tested
using Pearson's and Spearman's equations for parametric and
nonparametric data, respectively. P < 0.05 was accepted as
statistically significant.
Results
Urinary and plasma IL-8 levels
Plasma IL-8 levels from normal volunteers and patients fell
below the detection limit of ELISA. No detectable levels of IL-8
were found in the urine of any of the healthy volunteers as
previously described [13]. Similarly, IL-8 could not be detected in
P<0.05
Methylprednisolone pulse therapy
Fig. 3. Alteration of urinaiy IL-8 levels following methylprednisolone pulse
therapy in 17 patients. Symbols are: (0) IgA nephropathy; (•) lupus
nephritis; (0) cryoglobulinemia.
the urine from the minimal change nephrotic syndrome (MCNS),
focal glomerulosclerosis (FGS), and membranous nephropathy
patients. In contrast, elevated urinary IL-8 levels were detected in
17 out of 43 cases of IgA nephropathy (39.0%), prominently in 14
out of 15 cases showing acute onset or exacerbation (93.3%), in 4
of 6 cases of AGN (66.6%), in 11 of 15 cases of lupus nephritis
(73.3%) and in 2 of 4 cases of purpura nephritis (50%). It was also
detected in 1 of 1 case of membranoproliferative glomerulone-
phritis (MPGN) and 2 of 2 cases of cryoglobulinemia (Fig. 1). As
for thirteen lupus nephritis patients who experienced renal biop-
sies, glomerular appearance was classified on optical microscopy
as focal proliferative lupus nephritis (PLN, WHO Class III) in two
patients, diffuse proliferative lupus nephritis (DPLN, WHO Class
IV) in eight, and membranous lupus nephritis (MLN, WHO V) in
three. All patients with DPLN and one with PLN showed detect-
able level of urinary IL-8, whereas urinary IL-8 was not detected
in any patients with MLN. The activity index ranged from 0 to 18
(mean 6,5 1.3, mean SEM, N = 13), and specimens given as
activity index of more than 6.0 were considered to be active (Fig.
1).
Urinary IL-8 levels at acute onset or exacerbation
Acute onset or acute exacerbation, manifested by macroscopic
hematuria and/or an abrupt increase in urinary protein, was
observed in 25 patients with IgA nephropathy (15 cases), AGN (6
cases), MPGN (1 case), purpura nephritis (2 cases) and cryoglob-
ulinemia (1 case) (Fig. 1, open circles). In all cases except one with
IgA nephropathy and 2 with AGN, urinary IL.8 levels were
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Fig. 4. Immunohistochemical examination.
Expression of IL-8 protein in renal tissues was
detected using a specific monoclonal anti-
human IL-8 antibody as described in the
Methods. The sections were observed under
light microscopy at >< 320 magnification. A
representative result from one cryoglobulinemia
patient is shown here. IL-8-positive cells were
detected in glomerular capillaries.
increased. In 12 patients whose clinical courses could be followed
by sequential urine sampling, urinary IL-8 levels decreased as the
disease resolved (73.6 5.9 pg/mg creatinine vs. 25.1 6.4
pg/mg creatinine, P < 0.01; Fig. 2). Urinaiy IL-8 levels remained
elevated in 7 patients including 5 with IgA nephropathy, 1 with
MPGN and 1 with purpura nephritis even after the improvement
of clinical signs as evidenced by decreased urinary protein excre-
tion and improved urinary sediments.
Effects of methylprednisolone pulse therapy on urinaiy IL-8 levels
Seventeen patients (including 13 lupus nephritis patients, 3 IgA
nephropathy patients and 1 cryoglobulinemia patient) were
treated with methylprednisolone pulse therapy (500 mg/day, 3
days) during this study. Urinary IL-8 levels were elevated in 13 of
these patients at the start of therapy (Fig. 3). All patients showed
significant clinical improvement at four to eight weeks after the
initial pulse therapy as judged by physical findings and renal
functions. Concomitantly with the resolution of disease, urinary
IL-8 levels decreased in 13 patients who showed elevated urinary
IL-8 levels at the start of the therapy (98.4 32.7 pg/
mg creatinine vs. 19.3 8.2 pg/mg . creatinine, P < 0.05; Fig. 3).
IL-8 is produced locally in renal tissues
Local production of IL-8 in renal tissues was suggested by
elevated urinary level as opposed to undetectable plasma level of
IL-8 in patients with the various types of renal diseases that we
examined. To directly examine whether cells within the glomeruli
produced IL-8, renal tissues from 59 patients were examined
immunohistochemically for the presence of antigenic IL-8. In the
glomeruli from patients with undetectable urinary IL-8 levels,
IL-8 was not detected immunohistochemically (Table 1). IL-8-
positive cells were detected in glomerular capillaries (Fig. 4) when
immunostaining was performed on specimens obtained from
patients with IgA nephropathy, MPGN, lupus nephritis and
cryoglobulinemia (Table 1). The staining was specific to IL-8,
since control antibody did not give a positive staining (data not
shown). These results favored the notion that IL-8 was produced
locally in glomeruli of patients with glomerular lesions.
Possible involvement of IL-8 in leukocyte infiltration into
glomeruli
Since evidence is accumulating that IL-8 is essential for leuko-
cyte infiltration in acute inflammation [7], we examined the
relationship between leukocyte infiltration in glomeruli and uri-
nary IL-8 levels in 69 patients whose urines were collected at the
time of renal biopsy. The urinary IL-8 levels were elevated in 14
out of 17 patients with leukocyte infiltration in glomeruli whereas
only 6 out of 52 patients without leukocyte infiltration showed
elevated urinary IL-8 levels (Fig. 5).
Discussion
This study showed that the levels of immunoreactive IL-8 were
elevated in urine from patients with primary or secondary glomer-
ular diseases compared with healthy volunteers. Based on immu-
noblotting analysis on urine from patients with urinary tract
infection [13], urinary IL-8 was presumed to be intact, rather than
a degradation product without biological functions. Despite the
presence of IL-8 in urine, plasma IL-8 levels failed to elevate
above the detection limit, suggesting that IL-8 was produced
locally in the diseased renal tissue. This assumption is supported
by observations that resident cells, such as mesangial cells [11] and
endothelial cells [101 and epithelial cells [12] and leukocytes could
produce IL-8 in vitro. Immunohistochemical analyses confirmed
that immunoreactive IL-8-positive cells were found in the capil-
laries of the diseased glomeruli. However, in 28 out of 34 patients
with detectable urinary IL-8, IL-8 was not detected by immuno-
histochemical study in renal tissue obtained by renal biopsies. This
might be partially because we could not fully observe IL-8-positive
cells in the limited number of glomeruli obtained by renal biopsy
specimen. In addition, the detection of the IL-8-positive cells
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Fig. 5. Relationship between leukocyte infiltration in glomendi and urinary
IL-8 levels. Symbols are: (0) lupus nephritis; (•) IgA nephropathy; (U)
purpura nephritis; (0) cryoglobulinemia; (A) MPGN; (A) MCNS, FGS,
MN.
might be limited due to the low sensitivity of this immunohisto-
chemical method.
Elevated urinary IL-8 levels were observed in patients with IgA
nephropathy, AGN, purpura nephritis, cryoglobulinemia, MPGN
and lupus nephritis, but not in patients with MCNS, FGS and
membranous nephropathy. The most noticeable difference was
that glomeruli from the former group showed the infiltration of
polymorphonuclear cells and/or mononuclear cells and the pro-
liferation of mesangial cells, whereas those from the latter group
did not. In this study, the urinary IL-8 levels were increased in 14
out of 15 IgA nephropathy patients with acute onset or exacer-
bation, conditions in which polymorphonuclear leukocytes and
mononuclear cells in glomeruli are often observed [17]. Moreover,
we often observed infiltration of polymorphonuclear leukocytes
into glomeruli that stained positively with anti-IL-8 antibody in
immunohistochemical analyses (data not shown). As for thirteen
lupus nephritis patients who experienced renal biopsies, all pa-
tients with DPLN and one with PLN showed detectable level of
urinary IL-8, whereas urinary IL-8 was not detected in any
patients with MLN. These results suggest that IL-8, produced in
the glomeruli, promotes the infiltration of leukocytes, particularly
neutrophils into glomeruli in the process of renal injury.
IL-8 is known to promote neutrophil adhesion to endothelium
in vitro [18, 19] and to cause the release of reactive oxygen
metabolites [20] and degranulation of neutrophils [21]. Thus, it is
possible that neutrophil activation by IL-8 produced in diseased
glomeruli was also involved in glomerular injury. Thus, the
measurement of urinary IL-8 may detect the local inflammatory
events, particularly those related to both infiltration and activa-
tion of leukocytes, in the diseased glomeruli.
The efficacy of pulse therapy with a corticosteroid has been
established on lupus nephritis [22], IgA nephropathy [231, and
cryoglobulinemia [24] as judged by improvement of the prognosis.
However, the precise mechanism of the effects of glucocorticoids
on glomerular injury remains to be investigated. In this study,
urinary IL-8 levels decreased markedly in all patients after
treatment with pulse therapy. Glucocorticoids have been shown to
suppress IL-8 production at the transcriptional level in a human
fibrosarcoma cell line [25]. Although it is not clear at the moment
whether similar effects are exerted on mesangial, endothelial, or
epithelial cells, it is tempting to speculate that one of the
pharmacological actions of glucocorticoids might be the inhibition
of IL-8 production by activated resident cells and infiltrating
mononuclear cells. If this is the case, agents, which specifically
inhibit IL-8 production or block its biological functions, could be
used along with steroid pulse therapy.
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